Neovascular Age-related Macular Degeneration (nAMD) Clinical Trial
Official title:
Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for Neovascular Age-related Macular Degeneration (nAMD) in Portugal
This study is a prospective, observational, non-interventional, multicenter, open-label, single arm study in patients being treated for nAMD with brolucizumab in Portugal.
Naïve and pre-treated patients will be included after decision to start treatment with brolucizumab and consent is given. The baseline visit will be used to assess eligibility and collect baseline characteristics information. The study eye will be defined as the first eye treated during the study; the other eye will be considered as fellow eye. If both eyes are treated at baseline, the eye with the worse visual acuity will be chosen as the study eye (if the visual acuity is measured equal, the treating ophthalmologist defines the study eye upon his discretion). The follow-up visits will take place at a frequency defined as per investigator's discretion. Patients that have not received an intravitreal anti-VEGF injection or visited an eye specialist for at least 6 months will be discontinued from the observation. Retrospective data will be collected for switch patients starting treatment with brolucizumab for up to six months before baseline. Patients, already being treated with brolucizumab may also be included. Here, retrospective data will be collected since the first brolucizumab injection. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04543331 -
Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
|
||
| Recruiting |
NCT05904691 -
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
|
Phase 1 | |
| Completed |
NCT05282004 -
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
|
Phase 3 | |
| Completed |
NCT05269966 -
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
|
Phase 4 | |
| Completed |
NCT05161806 -
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
|
Phase 3 | |
| Recruiting |
NCT04657289 -
A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
|
Phase 3 | |
| Recruiting |
NCT06116890 -
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
|
Phase 2 | |
| Recruiting |
NCT06075147 -
The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
|
||
| Terminated |
NCT04746963 -
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05769153 -
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT05210803 -
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
|
||
| Recruiting |
NCT04514653 -
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
|
Phase 2 | |
| Not yet recruiting |
NCT06398080 -
An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
|
||
| Active, not recruiting |
NCT05989126 -
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
|
Phase 3 |